

## Supplementary Appendix

The following codes were used to identify conditions in the Danish National Patient Register:

- *Superficial thrombophlebitis*: ICD-8: 451.01; ICD-10: I80.0
- *Deep venous thrombosis in a lower limb*: ICD-8: 451.00; ICD-10: I80.1-I80.3
- *Pulmonary embolism*: ICD-8: 450.99; ICD-10: I26.0, I26.98
- *Liver cirrhosis*: ICD-8: 571.09, 571.90, 571.92, 571.99; ICD-10: K70.3, K71.7, K74.3, K74.5, K74.6
- *Non-cirrhotic liver disease*: ICD-8: 570.00–573.09 (excluding 571.09, 571.92, 571.90, 571.99), 070.01-070.09; ICD-10: K70.0- K70.9 (excluding K70.3), R74.0, K71.0–K77.8 (excluding K71.7, K74.3, K74.5, K74.6), B15–B19
- *Psychiatric disorders*: ICD-8: 291-301, 304; ICD-10: F10.4-F10.9, F11-F69
- *Obesity*: ICD-8: 277.9; ICD-10: E66
- *Fractures or trauma*: ICD-8: 800-929, 950-959; ICD-10: S00-T14
- *Surgery*: any surgery code from the Danish classification of surgical procedures (for the period 1977-1995) or NOMESCO classification (for the period 1996-2010)
- *Pregnancy or delivery*: ICD-8: 630-680; ICD-10: O00-O99
- *Alcoholism-related disease*: ICD-8: 291-291.9, 303-303.9, 980; ICD-10: F10.2, F10.7, F10.8, I42.6, G62.1, K29.2, G72.1, G31.2, T51, Z72.1

The following codes were used to identify cancers in the Danish Cancer Registry:

Hepatocellular carcinoma: ICD-10: C22.0

Cholangiocarcinoma: ICD-10: C22.1

Other liver cancers: ICD-10: C22.2, C22.3, C22.4, C22.7, C22.9

Lung: ICD-10: C33-C34

Urinary tract: ICD-10: C64-68, D090-091, D301-309, D411-419

Pancreas: ICD-10: C25

Buccal cavity and pharynx: C00-C14

Esophagus: ICD-10: C15

Larynx: ICD-10: C32

Breast: ICD-10: C50

Endometrium and ovary: ICD-10: C54-56, C570-574

Prostate: ICD-10: C61

Stomach: ICD-10: C16

Colon and rectum: ICD-10: C18-C20

Gallbladder and biliary tract: ICD-10: C23-C24

Lymphatic tissue: ICD-10: C81-90

Brain and nervous system: ICD-10: C69-72, C751-753, D32-33, D352-354, D42-43, D443-445

**Supplementary Table 1.** Observed (O) numbers and standardized incidence ratios (SIRs) with 95% confidence intervals (CIs) for cancer at selected sites in patients with venous thromboembolism (VTE) and non-cirrhotic liver disease (n=1,867) or liver cirrhosis (n=888).

Cancer sites	Patients with non-cirrhotic liver disease and VTE				Patients with liver cirrhosis and VTE			
	Complete follow-up period		First year of follow-up		Complete follow-up period		First year of follow-up	
	O	SIR (95% CI)	O	SIR (95% CI)	O	SIR (95% CI)	O	SIR (95% CI)
<b>Liver, total</b>	12	13.37 (6.90-23.35)	3	23.34 (4.81-68.14)	17	47.17 (27.46-75.54)	7	103.08 (41.34-212.35)
- Hepatocellular carcinoma	10	18.19 (8.71-33.46)	2	26.42 (3.20-95.37)	13	59.83 (31.82-102.31)	5	121.28 (39.29-282.57)
- Cholangiocarcinoma	0	-	0	-	1	30.45 (0.77-169.58)	1	161.91 (4.10-901.85)
- Other	2	7.73 (0.94-27.90)	1	24.76 (0.63-137.90)	3	27.22 (5.61-79.47)	1	48.78 (1.23-271.68)
<b>Other sites, total*</b>								
- Lung	27	2.35 (1.55-3.42)	9	5.24 (2.40-9.96)	14	2.92 (1.59-4.90)	6	6.46 (2.37-14.08)
- Urinary tract	6	0.84 (0.31-1.82)	2	1.91 (0.23-6.91)	6	2.01 (0.74-4.38)	5	8.86 (2.87-20.64)
- Pancreas	8	3.28 (1.41-6.46)	7	19.15 (7.68-39.44)	4	4.14 (1.13-10.60)	2	10.83 (1.31-39.10)
- Buccal cavity and pharynx	8	3.45 (1.49-6.80)	2	6.31 (0.76-22.77)	4	4.59 (1.25-11.76)	1	6.06 (0.15-33.75)
- Esophagus	3	2.52 (0.52-7.35)	0	-	5	10.55 (3.42-24.59)	2	23.70 (2.87-85.57)
- Larynx	2	2.40 (0.29-8.66)	0	-	1	2.72 (0.07-15.17)	0	-
- Breast	5	0.45 (0.14-1.04)	0	-	7	1.98 (0.79-4.07)	2	2.87 (0.35-10.35)
- Endometrium and ovary	3	0.90 (0.18-2.62)	0	-	2	1.60 (0.19-5.77)	1	3.88 (0.10-21.62)

- Prostate	10	1.09 (0.52-2.01)	2	1.66 (0.20-5.99)	4	1.08 (0.29-2.76)	1	1.56 (0.04-8.72)
- Stomach	3	1.76 (0.36-5.13)	1	3.87 (0.10-21.56)	3	4.27 (0.88-12.47)	1	7.02 (0.18-39.09)
- Colon and rectum	16	1.41 (0.80-2.29)	3	1.78 (0.37-5.19)	5	1.12 (0.36-2.61)	4	4.79 (1.30-12.27)
- Gallbladder and biliary tract	6	10.86 (3.99-23.67)	4	46.22 (12.57-118.32)	1	4.47 (0.11-24.90)	1	21.98 (0.56-122.42)
- Lymphatic tissue	8	2.08 (0.90-4.10)	0	-	5	3.52 (1.14-8.21)	2	7.44 (0.90-26.85)
- Brain and nervous system	7	2.10 (0.84-4.34)	1	2.12 (0.05-11.81)	4	3.60 (0.98-9.23)	1	4.73 (0.12-26.33)
- Metastases and non-specified cancers in lymph nodes	12	5.69 (2.94-9.95)	5	15.88 (5.14-36.99)	3	3.68 (0.76-10.74)	1	6.69 (0.17-37.29)

---

\* Not all sites shown